Microbix Biosystems Inc. · TSX:MBX
Microbix Biosystems — Investor Presentation (May 2025)
21 slides from Microbix Biosystems's investor presentation, May 15, 2025
Slide 1: Microbix Presentation: Growth & Profits from Supporting Next-Generation Diagnostics
TSX: MBX | OTCQX: MBXBF Microbix Presentation Growth & Profits from Supporting Next-Generation Diagnostics Spring 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about trends and objectives. Risks and uncertainties relating to such statements could cause actual outcomes to differ materially. Such risks include, among others, those related to operations, customers or markets, gro
Slide 3: Microbix – Growth & Profits, Backed by a Strong Balance Sheet
Microbix –Growth & Profits, Backed by a Strong Balance Sheet A global leader in infectious 3 state-of-the-art facilities diseases and a trusted partner Targeting annual sales fully-commissioned, modern and supplier to the largest ERP & eQMS implemented, diagnostics companies growth of >20% providing
Slide 4: Financials – Microbix Capital Structure
Financials – Microbix Capital Structure TSX: MBX • OTCQX: MBXBF Analyst Coverage Current Price $0.34 (05/14) Shares Outstanding (Basic) 141.0M** (Fully Diluted) 172.1M** David Martin 52 Week High $0.55 Target Price: $0.80 52 Week Low $0.29 Market Cap $47.9M Avg. Daily Volume ~123K (3 mos.) Cash and
Slide 5: Microbix Senior Management
Microbix Senior Management Cameron L. Groome Jim Currie, CPA Ken Hughes, Ph.D. CEO, President, and Director Chief Financial Officer Chief Operating Officer Has served on the MBX BoD and AC since Joined MBX as CFO in 2016 after several CFO Executive and biomedical scientist with 25 2012 and was appoi
Slide 6: Microbix Board of Directors
Microbix Board of Directors STRONG ALIGNMENT WITH 22M INSIDER-OWNED SHARES Martin Marino Dr. Peter M. Blecher Mark A. Cochran, Ph.D. Board Chairman Director HRGC Chair Mr. Marino has 30+ years of experience in Dr. Blecher, a longtime ER physician and pain Dr. Cochran was Executive Director of Johns
Slide 7: What Microbix Makes and Sells
What MicrobixMakes and Sells Antigen C$ Sales We grow, purify, and inactivate many $16,000 bacteria and viruses to make “Antigens,” $14,000 as critical ingredients in “Immunoassay” $12,000 $10,000 tests that detect antibodies in blood in $8,000 order to assess exposure to, or immunity $6,000 $4,000
Slide 8: Test Ingredients – Antigens
Test Ingredients – Antigens Grows, purifies, and inactivates native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies. Microbix provides antigens on a large scale for major international diagnostic manufacturers, most often as a critical sole-sourc
Slide 9: Test Controls – Quality Assessment Products (QAPs™)
Test Controls – Quality Assessment Products (QAPs™) QAPs Competitive Advantages Performance Formats Stability Full-genome & whole- Vial & FLOQSwab® formats Proven stability at room workflow, to best prevent to enable support of both temp (swabs) or 2-8°C systemic errors across all lab-based & point-
Slide 10: To Whom Microbix Sells
To Whom MicrobixSells Microbix has been selling to international test makers for decades – its Antigens forming the heart of millions of Immunoassays. It has over 100 such customers, many ordering > C$ 100K/yr of product. Over recent years, Microbix has added new categories of customers via its QAPs
Slide 11: Where Microbix Products are Used
Where MicrobixProducts are Used Our Ingredients (Antigens) and Medical Devices (QAPs) are in use around the world. Microbix products are available in more than 30 countries, directly or via partners. 11 TSX: MBX | OTCQX: MBXBF
Slide 12: Ensuring Confidence in Diagnostic Tests
Ensuring Confidence in Diagnostic Tests Makers, Regulators, Users, & Payors Need Proof They Work Our Products Help Ensure that Tests Microbix makes essential products that enable diagnostic Actually Work. This is Critical for tests to be made and sold. Many next generation Dx assays Correct Diagnosi
Slide 13: Kinlytic® – An FDA-Approved Clot-Buster Drug
Kinlytic® – An FDA-Approved Clot-Buster Drug Microbix owns the BLA of a well-established thrombolytic. Partnered with Sequel Pharma, LLC for re-launch of cell-culture derived LMW urokinase Kinlytic® Urokinase Microbix’s deep expertise in cell-culturing led to its securing rights to a clot-buster bio
Slide 14: Kinlytic® – An FDA-Approved Clot-Buster Drug
Kinlytic® – An FDA-Approved Clot-Buster Drug Refined project scope to Established Precise Costs Catheter Clearance Indication & Quotes from qualified vendors U.S. market as initial value-driver Removed risk for partners Prepared Due Diligence In 2024, Secured funding of Data Room & detailed project
Slide 15: Operations – Capabilities and Highlights
Operations – Capabilities and Highlights We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities Microbix now has over 120 staff across 3 adjacent sites CE Mark and/or FDA Registrations for 89 IVD “REDx” Molecular Test Controls and nearly 300 SKUs in total 265 Wat
Slide 16: Operations – Capabilities and Highlights
Operations – Capabilities and Highlights We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities 235 Watline (building 2) built-out and operational Semi-auto liquid-vial format QAPs Mfg. suite – 150,000/month capacity Semi-auto dried-swab format QAPs Mfg. suite –
Slide 17: Operations - Expanding Product Line & Revenue
Operations - Expanding Product Line & Revenue Microbix’s product line is rapidly expanding, as is our base of customers. Just in the past 6 months… October 2024 – Novel QAP for HSV Tests – Supporting “FFPE” tissue-sample testing and entering “molecular pathology” November 2024 – KOL presents HPV QAP
Slide 18: Financials – The Past Several Years
Financials – The Past Several Years Firmly EBITDA Positive Since Fiscal 2021 | Record Revenues & Net Earnings in Fiscal 2024 | Have Repurchased (& cancelled) >8.6 Million Shares Revenue Gross Margin 30,000,000 18,000 100% 25,000,000 16,000 14,000 80% 20,000,000 12,000 60% 15,000,000 10,000 8,000 10,
Slide 19: Microbix's Business Objectives – The Next Few Years
Microbix’sBusiness Objectives –The Next Few Years Cross-Selling – Sell every product MDx & PoCTs – Support growth of category across existing customer- Molecular & point-of-care-testing base of >100 Dx industry firms . via value-added product lines. New Clients – Identify & secure Multiplex Tests –
Slide 20: Key Takeaways about Microbix
Key Takeaways about Microbix Microbix has become a “go-to” partner regarding Cutting-Edge Capabilities & Real next-generation diagnostic tests. Its QAPs are often Revenue Growth Opportunities essential for approval/adoption of new lab-based and PoC tests. Capabilities Outcomes Both Dx & Rx Projects
Slide 21: Thank You
TSX: MBX | OTCQX: MBXBF Thank You Cameron Groome CEO, President, and Director cameron.groome@microbix.com TSX: MBX | OTCQX: MBXBF
Microbix Biosystems — Investor Presentation (May 2025) on 6ix